pg_0001

Medical data is for informational purposes only. You should always consult your family physician, or one of our referral physicians prior to treatment.

A New Approach to

Rheumatic Diseases

Efrain Olszewer, M.D.

p.778; reproduced by permission of the author and the publication.

Foundation for Eradication of Rheumatoid Disease

AKA The Arthritis Trust of America

7376 Walker Road, Fairview, Tn 37062

No matter how many nonsteroidal antiinflammatory, immuno-

suppressive, and cortisone-related drugs were introduced in the past

year as first option for rheumatic diseases, the improvement obtained

was poor because most of the time we only control the pain and the

inflammatory symptoms, but the disease continues to destroy the

tissues.

Because of this situation, four years ago we proposed a triple

approach for sero-negative and sero-positive rheumatic diseases with

clinical and laboratory results above what we originally expected.

The triple approach includes:

1. DMSO (Dimethylsulfoxide) one of the most powerful

antioxidants known, and has a strong antiinflammatory effect. It has

been used since 1940 as an industrial solvent, and after the studies

of Jacobs was included in 1960, for osteomuscular diseases.

In 1978 the FDA approved the use of DMSO for interstitial

cystitis, but there are multiple studies showing an improvement in

different pathologies with the use of DMSO.

In degenerative diseases like Osteoarthritis free radicals (FR)

attach and degenerate the cartilage, decreasing the space inbetween

the bones of the joint, and this contact will produce pain with

movement.

In inflammatory diseases, FR are closely related to leukotrines

synthesis as described in pathologies like rheumatic arthritis. In both

cases DMSO will decrease the synthesis of FR, inhibiting its

deleterious effect on the bone structures.

Experimental studies in animals confirmed that DMSO dis-

solves the collagen of the fundamental matrix, improving elastic

tissue and increasing the elimination of hydroxyproline, only in

patients with collagenopathies, but not in normal individuals.

2. Enzymo-Injection-Pressure (EIP) consists in using a com-

plex formula in order to create pressure points in the ailing joints; this

approach has antipain, antiinflammatory and fibrinolitic effects.

It works by a pressure mechanism that will stimulate the

amyelinated fibers that measure from 5 to 15 microns in diameter, and

send to the brain the pressure stimuli with a speed of 30 to100 meters

per second. By this method the pressure stimuli will always arrive first

at the brain regulatory center over the pain stimuli.

The formula (called F3) included in each 30cc multiple vial dose

the following:

Papain ........................... 0.005 grams

hyaluronidase ................ 0.001grams

trypsin ........................... 0.005 grams

UTP .............................. 0.001 grams

novocaine chloride ........ 0.100 grams

saline solution 0.9% ...... 30 cc

3. Mucopolysaccharides, also called glycoaminoglycans, formed

by the hyaluronic acid, chondroitan and dermatan sulphate, that are

components of the fundamental matrix, and are used to stimulate the

mitotic activity of the condrocytes to keep the cartilage integrity.

After a follow-up of three years in 36 eligible patients with

Osteoarthritis, we prepared a retrospective analysis that soon will be

published, where we obtained the following results:

a. From the 36 patients included in the follow up, 33 (91.66%)

had a complete recovery of the general signs and symptoms as: joint

swelling, joint pain, limitation of movements, morning rigidity,

crippling, partial social inactivity.

The other 3 (8.45%) had a partial recovery but much better than

obtained with traditional therapy, and without side effects.

b. The important aspect of thus study was that it included only

patients that had been using three or more different kinds of antirheu-

matic drugs as follows:

1.) 100% use nonsteroidal drugs

2.) 89% use or used cortisone

3.) 66.6% use or used oral gold salts

4.) 22.7% use or used IM gold salts

5.) 18% use or used different kinds of immunosuppressive

drugs

6.) 0% plasmapheresis

c. Thirty two (89%) of the patients were women and 4 (11%) men.

Our protocol included an intensive course of treatments for 5 weeks

and a maintenance therapy monthly.

d. Nine patients (25%) had a partial recurrence.

e. Multiple joint diseases were included: coxo-femoral, knee,

shoulder, hand (interphalangeal distal) cervical and lumbar backbone,

etc.

In the last two years we included patients with Rheumatoid

Arthritis and sero-negative rheumatic diseases. After more than 500

patients were treated we are extremely positive of this triple approach

for rheumatic disease and we present the following conclusions:

1. The triple approach therapy is highly successful in patients

with Rheumatoid Arthritis but it takes more treatments in the first part

of the therapy; however in our opinion this therapy modality keeps the

patients antisymptomatic for longer periods of time.

2. Patients with Ankylosing Spondylitis represent a small

number of our patients, but the improvement seen in these patients is

sometimes astonishing compared to the usual approach

(antiinflammatories and physiotherapy).

3. Other sero-negative rheumatic patients have variable results

that suggest more intensive studies in each particular disease.

4. Finally, patients with Rheumatoid Arthritis and Psoriasis,

Lupus Erythematosis and other autoimmune diseases complicated

with joint pathology need more attention, but it seems that we can get

an outstanding therapeutic result in a long term therapy. But we still

Efrain Olszewer, M.D.